Affimed NV Banner Image

Affimed NV

  • Ticker AFMD
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Affimed NV Logo Image
  • 51-200 Employees
  • Based in Heidelberg, Germany
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.
4.8 / 5.0 (93)

Affimed NV reports have an aggregate usefulness score of 4.8 based on 93 reviews.

Affimed NV

Most Recent Annual Report

Affimed NV
MOST RECENT 2023 Annual Report

Affimed NV does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Older/Archived Annual Reports

Affimed NV Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!